What should procurement teams verify before signing a multi-year vendor contract in the Digital Biomarkers Market?

Demand the analytical and clinical validation dossier for each specific endpoint, not the platform overall. Confirm data portability terms and algorithm version-control commitments in writing [12]. Read More

How do consumer-grade wearables compare with medical-grade devices for regulated use?

Consumer devices win on scale and cost but often lack raw-signal access, which regulators increasingly expect. Medical-grade hardware costs five to ten times more yet shortens submission review [1]. Read More

Who actually owns the data generated in a sponsored study within the Digital Biomarkers Market?

Ownership depends entirely on the consent architecture and vendor contract. Sponsors typically hold study data; platform vendors often retain rights to de-identified derivative models unless explicitly excluded [15]. Read More

What integration obstacle most often delays provider deployments?

Middleware. Fewer than half of provider organisations can ingest continuous device streams natively into their EHR, so each rollout requires custom interface work that adds two to three quarters [13]. Read More

Which emerging use case is least covered by current investment?

Perioperative recovery monitoring. Post-surgical complication detection has strong clinical economics but almost no dedicated vendor focus compared with cardiology and neurology [14]. Read More

How does the EU AI Act affect vendors operating in the Digital Biomarkers Market?

Most clinical algorithms fall under high-risk classification, requiring conformity assessment, risk management documentation, and post-market monitoring. Compliance overlaps substantially with existing MDR obligations [2]. Read More

Is acquisition or partnership the better entry route for a pharmaceutical sponsor?

Partnership suits sponsors running fewer than five sensor-enabled studies annually. Above that threshold, acquisition of an endpoint specialist typically returns better economics within three years [21]. Read More

Digital Biomarkers Market (2026 - 2035)

ID: MRFR/HC/10766-HCR 200 Pages Vikita Thakur Last Updated: September 15, 2026

Digital Biomarkers Market Research Report: Size, Share, Trend Analysis By Applications (Chronic Disease Management, Mental Health Monitoring, Personalized Medicine, Drug Development, Clinical Trials), By Technology (Wearable Devices, Mobile Health Applications, Remote Patient Monitoring, Telehealth Solutions), By End Use (Healthcare Providers, Pharmaceutical Companies, Research Organizations, Insurance Companies), By Data Source (Physiological Data, Behavioral Data, Psychological Data, Genetic Data) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Digital Biomarkers Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)18.6%

2025 Market SizeUSD 4.18 Billion

2035 Market SizeUSD 23.02 Billion

Key Players

Koninklijke Philips N.V.

Medtronic plc

Apple Inc.

Biogen Inc.

Huma Therapeutics

Evidation Health

Trends

Regulatory Qualification Turns Measurement into Evidence
Decentralized Trials Rebuilt the Demand Base
Reimbursement Finally Caught Up

Opportunities

Neurodegenerative Disease Endpoint Franchises
Emerging-Market Leapfrog Deployments
Data Monetisation and Endpoint-as-a-Service Models

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways |
1. 2.1 By Component |
2. 2.2 By Therapeutic Area |
3. 2.3 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Drivers Analysis |
1. 4.1 Regulatory Qualification of Sensor-Derived Endpoints |
2. 4.2 Decentralized & Hybrid Clinical Trial Adoption |
3. 4.3 Reimbursement Expansion & Value-Based Care |
4. 4.4 Sensor Cost Decline & Analytical Model Capability
5 Market Restraints Analysis |
1. 5.1 Clinical Validation Cost & Evidence Burden |
2. 5.2 Data Privacy, Consent & Cross-Border Transfer |
3. 5.3 Interoperability Gaps & Proprietary Formats |
4. 5.4 Clinician Workflow Burden & Alert Fatigue |
5. 5.5 Reimbursement Uncertainty Outside Pilot Programmes
6 Market Opportunity Analysis |
1. 6.1 Neurodegenerative Disease Endpoint Franchises |
2. 6.2 Emerging-Market Leapfrog Deployments |
3. 6.3 Data Monetisation & Endpoint-as-a-Service Models |
4. 6.4 Payer-Led Population Risk Stratification |
5. 6.5 Regulatory-Grade Software Toolchains |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Foundation Models & Predictive Analytics |
2. 8.2 Platform Economics & Margin Migration |
3. 8.3 Endpoint Standardisation & Pre-Competitive Consortia |
4. 8.4 Integration into Routine Care Delivery
9 Segmentation Analysis |
1. 9.1 By Component | |
  1. 9.1.1 Data Collection Tools | |
  2. 9.1.2 Data Integration & Analytics Platforms |
2. 9.2 By Data Source | |
  1. 9.2.1 Wearables | |
  2. 9.2.2 Smartphones & Mobile Apps | |
  3. 9.2.3 Implantables | |
  4. 9.2.4 Ingestibles | |
  5. 9.2.5 Other Sources |
3. 9.3 By Therapeutic Area | |
  1. 9.3.1 Neurological Disorders | |
  2. 9.3.2 Cardiovascular Disorders | |
  3. 9.3.3 Diabetes & Metabolic | |
  4. 9.3.4 Respiratory Diseases | |
  5. 9.3.5 Sleep & Behavioural Health | |
  6. 9.3.6 Oncology | |
  7. 9.3.7 Other Areas |
4. 9.4 By Clinical Practice | |
  1. 9.4.1 Monitoring Digital Biomarkers | |
  2. 9.4.2 Diagnostic Digital Biomarkers | |
  3. 9.4.3 Predictive & Prognostic Digital Biomarkers | |
  4. 9.4.4 Response Digital Biomarkers | |
  5. 9.4.5 Safety & Susceptibility Digital Biomarkers |
5. 9.5 By End User | |
  1. 9.5.1 Pharmaceutical & Biotech Companies | |
  2. 9.5.2 Healthcare Providers | |
  3. 9.5.3 Payers | |
  4. 9.5.4 Healthcare & Research Institutes | |
  5. 9.5.5 Others
10 Competitive Landscape |
1. 10.1 Market Share Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Koninklijke Philips N.V. | |
  2. 10.3.2 Medtronic plc | |
  3. 10.3.3 Apple Inc. | |
  4. 10.3.4 Biogen Inc. | |
  5. 10.3.5 Huma Therapeutics | |
  6. 10.3.6 Evidation Health | |
  7. 10.3.7 AliveCor Inc. | |
  8. 10.3.8 Koneksa Health | |
  9. 10.3.9 Biofourmis | |
  10. 10.3.10 Empatica Inc. | |
  11. 10.3.11 ActiGraph LLC | |
  12. 10.3.12 IXICO plc
11 Recent Developments & News
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Citations |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions (FAQs)
15 LIST OF TABLES |
TABLE 1 Global Digital Biomarkers Market Size & Forecast, by Revenue (USD billion), 2021–2035 |
TABLE 2 Global Digital Biomarkers Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Impact on CAGR, Geographic Relevance & Timeline |
TABLE 4 Restraint Impact Analysis – Impact on CAGR, Geographic Relevance & Timeline |
TABLE 5 Global Digital Biomarkers Market Size, by Region, 2021–2035 (USD billion) |
TABLE 6 North America Digital Biomarkers Market Size, by Country, 2021–2035 (USD billion) |
TABLE 7 Europe Digital Biomarkers Market Size, by Country, 2021–2035 (USD billion) |
TABLE 8 Asia-Pacific Digital Biomarkers Market Size, by Country, 2021–2035 (USD billion) |
TABLE 9 South America Digital Biomarkers Market Size, by Country, 2021–2035 (USD billion) |
TABLE 10 Middle East & Africa Digital Biomarkers Market Size, by Country, 2021–2035 (USD billion) |
TABLE 11 Global Digital Biomarkers Market Size, by Component, 2021–2035 (USD billion) |
TABLE 12 Global Digital Biomarkers Market Size, by Data Source, 2021–2035 (USD billion) |
TABLE 13 Global Digital Biomarkers Market Size, by Therapeutic Area, 2021–2035 (USD billion) |
TABLE 14 Global Digital Biomarkers Market Size, by Clinical Practice, 2021–2035 (USD billion) |
TABLE 15 Global Digital Biomarkers Market Size, by End User, 2021–2035 (USD billion) |
TABLE 16 North America Digital Biomarkers Market Size, by Component & Data Source, 2021–2035 (USD billion) |
TABLE 17 Europe Digital Biomarkers Market Size, by Therapeutic Area & End User, 2021–2035 (USD billion) |
TABLE 18 Asia-Pacific Digital Biomarkers Market Size, by Component & Clinical Practice, 2021–2035 (USD billion) |
TABLE 19 South America Digital Biomarkers Market Size, by Data Source & End User, 2021–2035 (USD billion) |
TABLE 20 Middle East & Africa Digital Biomarkers Market Size, by Therapeutic Area, 2021–2035 (USD billion) |
TABLE 21 Competitive Benchmarking Matrix – Global Digital Biomarkers Market, 2026 |
TABLE 22 Company Profiles – Key Players, Global Digital Biomarkers Market |
TABLE 23 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 24 Report Scope & Methodology Summary |
TABLE 25 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Global Digital Biomarkers Market – Market Dynamics Overview (Drivers, Restraints, Opportunities) |
FIGURE 2 Industry Value Chain Analysis – Sensor to Evidence |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend & Forecast, 2021–2035 (USD billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Market Share by Component, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Data Source, 2025 (%) |
FIGURE 8 Market Share by Therapeutic Area, 2025 (%) |
FIGURE 9 Market Share by Clinical Practice, 2025 (%) |
FIGURE 10 Market Share by End User, 2025 (%) |
FIGURE 11 Regional Market Share Distribution, 2025 (%) |
FIGURE 12 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 13 Country-Level Revenue Contribution – Top 10 Markets, 2025 |
FIGURE 14 Competitive Landscape – Estimated Revenue Share Distribution, 2026 |
FIGURE 15 Strategic Positioning Matrix – Capability vs Regulatory Depth |
FIGURE 16 Regulatory Milestone Timeline, 2023–2035

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Component	Data Collection Tools; Data Integration & Analytics Platforms	Data Collection Tools	Data Integration & Analytics Platforms
By Data Source	Wearables; Smartphones & Mobile Apps; Implantables; Ingestibles; Other Sources	Wearables	Implantables
By Therapeutic Area	Neurological Disorders; Cardiovascular Disorders; Diabetes & Metabolic; Respiratory Diseases; Sleep & Behavioural Health; Oncology; Other Areas	Neurological Disorders	Oncology
By Clinical Practice	Monitoring; Diagnostic; Predictive & Prognostic; Response; Safety & Susceptibility	Monitoring Digital Biomarkers	Predictive & Prognostic Digital Biomarkers
By End User	Pharmaceutical & Biotech Companies; Healthcare Providers; Payers; Healthcare & Research Institutes; Others	Pharmaceutical & Biotech Companies	Payers
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Component

Sub-Segment	Key Trend
Data Collection Tools	Sensor bill-of-materials cost decline pushing hardware toward commodity pricing.
Data Integration & Analytics Platforms	Regulatory-grade pipelines with audit trails becoming a procurement requirement.

Hardware still captures the larger revenue pool, but the strategic centre of gravity has already shifted. Buyers who once evaluated devices now evaluate whether a vendor can defend an algorithm in front of a regulator.

By Data Source

Sub-Segment	Key Trend
Wearables	Wrist-worn medical clearances extending consumer hardware into regulated workflows
Smartphones & Mobile Apps	Zero-hardware deployment models scaling rapidly in South Asia and Latin America
Implantables	Uninterrupted telemetry preferred for cardiology regulatory submissions.
Ingestibles	Adherence verification gaining traction in psychiatry and tuberculosis therapy.
Other Sources	Ambient and voice sensing emerging for cognitive and respiratory assessment.

Source diversity is increasing rather than consolidating. Sponsors now routinely combine two or three modalities per study, which is precisely what drives platform demand.

By Therapeutic Area

Sub-Segment	Key Trend
Neurological Disorders	Composite digital endpoints entering regulatory qualification pipelines
Cardiovascular Disorders	Population-scale arrhythmia screening generating clinical referral volume.
Diabetes & Metabolic	Continuous glucose ecosystems expanding into pre-diabetes populations
Respiratory Diseases	Exacerbation prediction models reaching clinically actionable lead times
Sleep & Behavioural Health	Consumer sleep metrics migrating into formal clinical assessment
Oncology	Performance status and toxicity capture supplementing clinician grading.
Other Areas	Rare disease and musculoskeletal niches funded by patient advocacy groups

Therapeutic concentration reflects measurement difficulty more than disease prevalence. Where existing instruments are blunt, continuous capture delivers the largest incremental value.

By Clinical Practice

Sub-Segment	Key Trend
Monitoring Digital Biomarkers	Anchored by reimbursed chronic disease and post-discharge programmes
Diagnostic Digital Biomarkers	Triage applications reducing unnecessary specialist referrals
Predictive & Prognostic Digital Biomarkers	Risk stratification tied directly to value-based contract performance.
Response Digital Biomarkers	Treatment efficacy signals shortening trial readout timelines
Safety & Susceptibility Digital Biomarkers	Continuous adverse event detection strengthening pharmacovigilance.

Monitoring dominates today because it is the only category with mature reimbursement. Predictive applications grow fastest because they change clinical decisions rather than merely documenting them.

By End User

Sub-Segment	Key Trend
Pharmaceutical & Biotech Companies	Portfolio-wide endpoint standardisation replacing study-by-study procurement.
Healthcare Providers	Reimbursement availability now the primary gate on adoption pace
Payers	Cost-avoidance modelling driving direct vendor contracting
Healthcare & Research Institutes	Grant-funded validation cohorts underpinning regulatory dossiers
Others	Employers and CROs entering as intermediary purchasers

Buyer mix is broadening in a way that changes pricing power. Sponsors tolerate premium rates; payers and providers will not, which pushes vendors toward tiered commercial architectures over the forecast decade.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”